SeqOne, a leader in AI-driven genomic analysis, has announced a definitive agreement to acquire Congenica, a UK-based digital health company spun out of the Wellcome Sanger Institute. The acquisition creates the largest global “software pure player” in clinical genomics, serving over 160 laboratories across more than 30 countries. This strategic move strengthens SeqOne’s position as a central force in the rapidly evolving field of personalized medicine. Founded in 2012, Congenica has built a strong reputation for clinical excellence, supporting more than 25 public and private laboratories, including multiple NHS Genomics Laboratory Hubs, Genomics England, and the Hong Kong Genomic Program. Its Clinical Decision Support Platform is widely recognized for enabling rapid, accurate interpretation of complex genomic data, particularly in rare diseases and oncology. SeqOne’s AI-powered platform specializes in Next-Generation Sequencing (NGS) analysis, offering clinical decision-support tools that help molecular labs deliver fast, scalable, and precise genetic insights. By combining SeqOne’s advanced AI capabilities with Congenica’s proven clinical expertise and interpretation services, the merged entity will deliver a unified solution capable of transforming vast genomic datasets into actionable, real-time clinical insights. This integration is critical as the cost of whole-genome sequencing has dropped dramatically, leading to a “data tsunami” — the real bottleneck now lies in interpreting the data, not generating it. Martin Dubuc, CEO of SeqOne, emphasized the importance of software innovation in advancing personalized medicine. He highlighted that the acquisition enhances SeqOne’s growth trajectory, expands its global footprint, and deepens its presence in the UK — a global leader in genomics since the 100,000 Genomes Project. The combined company will continue to support existing Congenica customers, ensuring service continuity while offering access to an expanded, integrated product suite. The deal follows a period of strong growth for SeqOne, which doubled its revenue and expanded from three to over 30 countries in just one year. It also comes after the acquisition of Life & Soft in April, which broadened SeqOne’s capabilities into multi-omics and virology. A recent €20 million funding round from top-tier venture capital firms has further fueled its strategy to consolidate the fragmented genomics software market and build a comprehensive software operating system for clinical genomics. The combined company will maintain a significant UK presence at the Wellcome Sanger Institute, ensuring continuity of research and clinical collaboration. Dr. Richard Scott, CEO of Genomics England, praised Congenica’s past contributions and expressed confidence in the new entity’s ability to continue advancing rare disease diagnosis. Dr. Andy Richards CBE, Chairman of Congenica, affirmed that SeqOne’s vision and resources are best positioned to carry forward Congenica’s legacy and serve patients globally. The financial terms of the transaction remain undisclosed. With its expanded capabilities and global reach, the merged entity is poised to play a pivotal role in overcoming the interpretation bottleneck in genomics, accelerating diagnoses for rare diseases, and enabling more precise, personalized cancer therapies. The acquisition marks a major milestone in the journey toward making personalized medicine accessible and scalable worldwide.